Pharmacy Compounding Accreditation FAQ — PCAB, USP 795, 797 & 800
Last updated: April 2026
Last updated: April 2026
15 expert answers on PCAB accreditation, USP compliance, 503A vs. 503B distinctions, state enforcement timelines, and common inspection deficiencies. For an overview of IHS's compounding pharmacy consulting services, see our PCAB Accreditation service page.
Frequently Asked Questions
What is PCAB accreditation and who needs it?
PCAB (Pharmacy Compounding Accreditation Board) is the premier accreditation credential for compounding pharmacies, administered through ACHC. PCAB accreditation demonstrates compliance with USP Chapters 795, 797, and 800 through independent third-party verification. Fewer than 1% of all U.S. pharmacies hold PCAB accreditation, while 21% of dedicated compounding-volume pharmacies do (APC 2023–2024 Demographic Survey). Organizations that benefit most: dedicated 503A compounding pharmacies; multi-state operations where PCAB is required for nonresident licensure (WA, OH); pharmacies approaching M&A transactions; and 503B outsourcing facilities.
What is the difference between USP 795, 797, and 800?
USP 795 governs non-sterile compounding — creams, capsules, oral liquids. The 2023 final version introduced a water activity metric and stricter BUD defaults. USP 797 governs sterile compounding — the most complex and most surveyed chapter. The 2023 version replaced the old risk-level framework with a Category 1/2/3 BUD continuum and added Designated Person designation, semi-annual gloved fingertip sampling, media fill testing, and category-specific environmental monitoring requirements. USP 800 governs hazardous drug handling for all NIOSH-listed drugs. All three chapters simultaneously achieved final enforceable status on November 1, 2023.
What changed with the revised USP Chapter 797 effective November 2023?
Five major changes: (1) Risk-level framework (low/medium/high) replaced by Category 1/2/3 BUD continuum tied to environmental control level. (2) Formal Designated Person designation required. (3) Semi-annual gloved fingertip and thumb sampling mandated for all sterile compounding personnel. (4) Media fill testing documentation required before personnel may manipulate patient drugs. (5) Scientifically validated shipping system validation required for all products in transit. Most compounding pharmacies needed substantial SOP and procedure updates across all five categories.
What is the difference between a 503A and 503B compounding pharmacy?
The DQSA (November 2013) bifurcated compounding into two tracks. 503A pharmacies compound patient-specific prescriptions, regulated by state boards under USP standards. 503B outsourcing facilities register with FDA and may compound for office stock without patient-specific prescriptions, subject to cGMP requirements and annual FDA establishment fees ($20,726 for non-small businesses in FY2026, FDA). As of March 2026, exactly 83 active 503B facilities are FDA-registered (FDA). 503B consulting requirements and costs are substantially more complex than 503A.
How much does PCAB accreditation cost?
ACHC does not publish a universal rate card. Historical baseline: $1,250–$5,000 under PCAB's original pricing; current fees are higher. APC members receive a $1,000 discount. No annual maintenance fees — costs consolidated into triennial survey. IHS consulting fees: $5,000–$10,000 for operational audit and mock survey; $3,000–$7,000 for regulatory remediation; ~$4,000 plus ~$1,000 for customized SOPs for full preparation. Hourly rates: $75–$300+/hour depending on specialization. See our PCAB Cost Guide for full breakdown.
How long does the PCAB accreditation process take?
7 to 8 months from engagement to accreditation for organizations with completed baseline state inspections. Full de novo build from non-compliant state: 12 to 18 months. Timeline: comprehensive gap assessment (weeks 1–2), SOP development (weeks 3–14), mock survey and remediation (weeks 15–18), application submission (week 19), on-site survey (months 5–8). PCAB runs on a 36-month cycle; renewal must begin at least 9 months before expiration.
Does PCAB accreditation satisfy state board of pharmacy USP compliance requirements?
PCAB demonstrates rigorous independent compliance with USP 795, 797, and 800 — the same standards most state boards enforce. But state requirements and PCAB are not legally identical. Washington and Ohio specifically require PCAB for nonresident licensure. Other states accept PCAB as evidence of compliance posture but may also conduct independent inspections. IHS provides state-specific guidance in every engagement.
What are the most common deficiencies found during PCAB inspections?
From ACHC's 2024 Surveyor Quality Review: (1) Equipment calibration and maintenance — 48% citation rate, most cited in 2024. (2) Safe storage, labeling, and handling — 41%. (3) Shipping system validation — 37%. (4) Designated Person designation — 31%. (5) Personnel training and competency — over 25%. Gloved fingertip/thumb sampling gaps and media fill testing documentation failures are also frequently cited under USP 797 (ACHC 2024 Surveyor Quality Review).
Is PCAB accreditation required or voluntary?
Mandatory in Washington and Ohio for nonresident licensure. Functionally required for most multi-state operations given: AMA formal recommendation that physicians use exclusively PCAB-accredited pharmacies; California's $8,500 nonresident sterile compounding license (California Board of Pharmacy); PE due diligence treating accreditation as prerequisite for 6x–10x EBITDA valuations. For pharmacies dependent on physician referral networks or multi-state operations, PCAB is a competitive necessity regardless of formal mandate.
What is the difference between PCAB and NABP VPP accreditation?
PCAB focuses specifically on compounding pharmacy quality through ACHC. NABP's Verified Pharmacy Program (VPP) is broader — covering dispensing operations, patient safety, and general pharmacy quality. For dedicated compounding pharmacies, PCAB is more directly recognized in physician referral networks and state board contexts. Specialty pharmacies that both compound and dispense commercial drugs sometimes pursue both credentials. See our PCAB vs. NABP VPP comparison.
What is a Designated Person and why is this role required under new USP standards?
The Designated Person (DP) is formally appointed to oversee the compounding quality program under new USP 795 and 797 frameworks. Responsibilities include quality oversight, deviation management, training program oversight, and regulatory compliance monitoring — documented in writing. The DP designation carries a 31% PCAB citation rate when absent or inadequately documented. USP frameworks treat this as a 1.0 FTE quality leadership role, not a part-time administrative function.
What is media fill testing and what happens if it fails?
Media fill testing requires sterile compounding personnel to simulate the compounding process using microbiological growth media instead of active drug. It verifies that each compounder's aseptic technique does not introduce microbial contamination. Personnel must pass before they may manipulate actual patient drugs, and must pass ongoing periodic challenges. A failure means the compounder cannot perform sterile compounding until the failure is investigated, root cause identified, retraining completed, and a successful repeat test is documented. IHS builds media fill testing schedules, documentation protocols, and failure response procedures into every sterile compounding engagement.
Which states require PCAB accreditation for nonresident compounding pharmacy licensure?
Washington and Ohio currently require verifiable PCAB accreditation for nonresident licensure. The enforcement wave is ongoing: Kentucky began enforcing revised USP chapters January 1, 2026; Ohio extended its grace period through February 28, 2027. IHS monitors state board developments and provides current state-specific guidance in every engagement.
What are the PCAB accreditation requirements for sterile compounding?
Under USP 797, PCAB assesses: Designated Person designation; initial and ongoing competency assessments; semi-annual gloved fingertip/thumb sampling; media fill testing documentation; cleanroom environmental monitoring at category-appropriate frequencies; temperature, humidity, and pressure differential documentation; Category 1/2/3 BUD assignment; shipping system validation; Master Formulation Records and Compounding Records; and deviation and CAPA documentation for all environmental excursions.
How do you maintain PCAB accreditation after earning it?
PCAB runs on a 36-month cycle with no annual fees. Ongoing requirements: continue all USP compliance activities (environmental monitoring, PT sampling, media fills, competency assessments); document all deviations and CAPAs; maintain equipment calibration logs; update SOPs when procedures change; monitor state board rule changes; initiate renewal at least 9 months before expiration. Significant operational changes — new Designated Person, modified compounding procedures, new test categories — may require ACHC notification and documentation updates. IHS offers post-accreditation compliance monitoring retainers.
Ready to Begin PCAB Preparation?
Schedule a gap assessment with Thomas G. Goddard, JD, PhD. IHS will assess your current USP 795/797/800 compliance posture and give you a clear roadmap to PCAB accreditation.